Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Carbone

Showing results (221-230 of 283) with videos related to

Pageof 29
Sort By:
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
BMC Cancer|May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medicationsDaniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcomeDavid P Carbone, I Frank Ciernik, Michael J Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2019
Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary AdenocarcinomaGwendolen Lorch, Karthigayini Sivaprakasam, Victoria Zismann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Proteogenomic Analysis of Surgically Resected Lung AdenocarcinomaMichael F Sharpnack, Nilini Ranbaduge, Arunima Srivastava, et al.
Clinical Lung Cancer|July 27, 2025
Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung CancerJohn Sharp, Philip Young, Songzhu Zhao, et al.
Pageof 29

Showing results (221-230 of 283) with videos related to

Sort By:
Pageof 29
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.
BMC Cancer|May 8, 2020
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medicationsDaniel Spakowicz, Rebecca Hoyd, Mitchell Muniak, et al.
Cancer|January 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancerJacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcomeDavid P Carbone, I Frank Ciernik, Michael J Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2019
Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary AdenocarcinomaGwendolen Lorch, Karthigayini Sivaprakasam, Victoria Zismann, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Proteogenomic Analysis of Surgically Resected Lung AdenocarcinomaMichael F Sharpnack, Nilini Ranbaduge, Arunima Srivastava, et al.
Clinical Lung Cancer|July 27, 2025
Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung CancerJohn Sharp, Philip Young, Songzhu Zhao, et al.
Pageof 29